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ABSTRACT 
Background: Delays in initiating elective inpatient chemotherapy can decrease patient satisfaction and 
increase length of stay. At our institution, we observed that 86% of patients admitted for elective 
chemotherapy experienced a delay (greater than 6 hours) with a median time to chemotherapy of 18.9 
hours. We developed a process improvement initiative to improve time to chemotherapy for elective 
chemotherapy admissions.  
Methods: Our outcome measure was time from admission to chemotherapy administration in patients 
admitted for elective chemotherapy. Process measures were identified and monitored. We collected 
baseline data and utilized performance improvement tools to identify key drivers. We focused on these 
key drivers to develop multiple plan-do-study-act (PDSA) cycles to improve our outcome measure. Once 
we started an intervention we collected data every two weeks to assess our intervention. 
Results: At the time of interim analysis, we observed a median decrease in time to chemotherapy 
administration from 18.9 hours to 8.85 hours (p value:0.005). Median time to lab resulted decreased from 
3.17 hours to 0.00 hours. There was no change in time from signature to nurse releasing the 
chemotherapy. We noticed more providers were signing the chemotherapy prior to patient admission.  
Conclusions: By implementing new admission workflows, optimizing our use of the Electronic Medical 
Record to communicate among providers, and improving pre-admission planning we were able to reduce 
our median time to chemotherapy for elective admissions by 53.2%. Improvement still needed to meet 




Patients admitted to the hospital for elective chemotherapy are medically stable, however, numerous 
processes can cause delays in initiating chemotherapy[1]. These delays lead to wasted time for the patient, 
decreased patient satisfaction, and unnecessary prolonged length of stay (LOS)[2, 3]. While few studies 
have evaluated improvement in the inpatient setting[1, 4], in the outpatient setting, studies have shown that 
decreasing wait times can impact the quality of care and improve patient satisfaction.[5-7] In addition to 
improving patient satisfaction with decreased wait times, decreasing length of stay may reduce hospital 
related complications[8-10] and cost of care, not to mention reduce resource utilization.[11, 12]  
As a result, using Institute for Healthcare Improvement model for improvement[13] and as part of the 
American Society of Clinical Oncology quality training program, we developed a new workflow to 
decrease time to chemotherapy administration in patients admitted electively to an oncology unit. 
Quality Improvement (QI) Initiatives at our institution do not require IRB approval, but are submitted to 
our institutional QI registry database. 
Methods 
A multidisciplinary team of physicians, pharmacists, nurses, administrators, information technology 
analysts, pharmacy technicians, and physician assistants participated in discussions and implementation 
of new processes. We defined a delay in chemotherapy as greater than 6 hours. This definition was based 
on an informal discussion with patients and physicians regarding an acceptable time for chemotherapy 
initiation. Time from admission to chemotherapy was defined as time of initial vital signs (best 
documentation of when the patient arrived on the unit) until time of chemotherapy administration. Length 
of stay was calculated using time of initial vitals to time of discharge. Other process measure endpoints 
were determined by EPIC timestamps. 
 
Aim Statement 
We aimed to reduce the time from admission to initiation of chemotherapy by 68.3%, from a median of 
18.9 hours to a median of 6 hours over 6 months from April to October, 2017. 
 
Plan  
A process map was developed (Appendix Figure 1). For baseline analysis, we reviewed charts for 
patients electively admitted for chemotherapy during the month of February, 2017 (24 cases). We 
measured time from admission to chemotherapy for each elective admission. Other key process measures 
were identified and median times for each process were calculated (Appendix Figure 2). Chemotherapy 
regimen type did not affect time to chemotherapy (Appendix Figure 3). Data were analyzed using QI 
macros software (QIMacros, Denver, CO).  
Do  
Using QI tools such as a fishbone diagram[14] and Pareto Chart [15], we identified several processes causing 
delays in initiating chemotherapy. We then constructed a PICK chart (Figure 1), to determine our 
interventions: Improve communication between physician and nurses concerning signing of 
chemotherapy, draw labs prior to admission, and improve time to chemotherapy signature.  
1) The first intervention was implemented on 6/22/17. A column in EPIC was added to the nurses’ 
multi-provider screen so they could visualize when the chemotherapy had been signed.  
2) The second intervention started on 7/19/17. Patients who arrived at the hospital prior to 4pm 
would have their labs drawn prior to admission. 
3) The third intervention started on 7/28/17. Physicians were notified to sign chemotherapy prior to 
their patient’s admission. 
Study  
Data after each Plan-Do-Study-Act (PDSA) [16] implementation was collected from 6/22/17 to 10/30/17 at 
2 week intervals. P values were calculated using two tailed t-tests. 
Act 
After reviewing data from the first intervention in mid July 2017, we decided to make a change to the 
intervention. In addition to communication facilitated through the Electronic Medical Record (EMR), we 
also discussed all new elective admissions at interdisciplinary rounds. At the same time we were 
developing our new workflow to have labs drawn prior to admission. On 7/19/17 all patients who arrived 
for admission prior to 4pm had labs drawn prior to registering for admission. This resulted in an 
immediate reduction in time to labs resulted and this intervention was adopted as part of our standard 
workflow. Our last intervention implemented on 7/28/17. This intervention helped improve our time to 
chemotherapy and was adopted.   
Results 
 
Patient characteristics at baseline and for each PDSA cycle are listed in the appendix (Appendix -Table 
1). Median time from admission to initiating chemotherapy was 18.9 hours. Median times for each step in 
the process were also calculated (Appendix – Figure 2). 
Our first PDSA cycle period (15 admissions – Appendix Table 1) resulted in no change in time from 
signature to nurse releasing chemotherapy.  Time to chemotherapy for this PDSA was 21.9 hours 
Our second PDSA cycle period (7 admissions - Appendix Table 1), resulted in a decrease from time of 
admission to labs resulted from a median: 3.17 hrs (n=38) to 0.00 hours (n=7) (Appendix Figure 4). 
Median time to chemotherapy for this PDSA was 24.9 hours. 
Our third PDSA cycle period (50 admissions- Appendix Table 1), resulted in an increase in chemotherapy 
signatures prior to admission from 16% prior to the intervention (n=45) to 37% (n=50) after the 
intervention. Median Time to chemotherapy for this PDSA was 8.85 hours.  
Based on data from April to October 2017 the median time from admission to start of chemotherapy 
decreased from 18.9 hours to 8.85 hours (p value: 0.005). Average LOS was 161.37 (SD: 141.59) hours at 
baseline and 125.94 hours (SD: 82.34) after all 3 PDSA cycles were implemented – a 22% decrease in 
LOS (p value: 0.2847). 
Patients who were admitted for chemotherapy, but were not clinically stable were included in this analysis 
(total cohort n=20). Many of the patients with significant delays over 36 hours fell into this subgroup 
(n=8), with a median time to chemotherapy of 29.38 hours. Exclusion of these patients from the post 
intervention group (n=4) still did not result in use reaching our goal of 6 hours (Median – 8.64 hours). 
Discussion  
Patient centered care is important in healthcare delivery and was the focus of this initiative. While we 
were successful in decreasing our time to chemotherapy initiation by 53.2% at the time of this analysis, 
we had not yet reached our goal (6 hours). 
In our cohort, our EMR based solution to improve communication was not as effective as we had hoped. 
This may have been due a poor understanding of which EMR screens the nurses are utilizing most, or an 
under-appreciation of the fact that nurses spend a significant amount of time in direct patient contact.  
Changing the admission workflow to have patient’s labs drawn prior to arrival did not have an immediate 
effect on time to chemotherapy, but we believe it contributed to the overall improvement. The slight 
increase in time to chemotherapy during PDSA 1 and 2 was likely due to disruption in the normal 
workflow as this can result in an initial worsening of outcome measures prior to seeing the improvement. 
Since PDSA #2 was a key driver and the process measure improved dramatically, we moved on to the 
next PDSA cycle. We focused on the process and key drivers as leading indicators, understanding that the 
outcome measure, often considered a lagging indicator, would follow.  Our third intervention included 
signing chemotherapy prior to admission reinforcing the point that pre-preparation is an effective strategy. 
Even though approaches have been made to transfer inpatient cancer care to the outpatient setting with 
success[17, 18], this might not always be possible in the hematologic malignancy population given 
complexity of treatment regimen and need for close monitoring.  
The major limitation to our study is that our data is from a single institution, however most process 
improvement initiatives begin at single institutions prior to scaling it up across a healthcare network. We 
included all patients that were admitted electively, including those who were not clinically stable for 
chemotherapy. Including these patients impacted negatively on our initiation to chemotherapy time, but 
doing so better reflects actual practice. Our next steps is to improve our pre-admission process to ensure 
that all patients have appropriate IV access prior to arriving to the inpatient oncology unit and ensuring 
that they are stable and ready to receive chemotherapy with a pre-admission telephone triage 24-hour 
prior to admission. This has been successful in prior studies[5]. 
Another limitation of the study was inability to accurately measure LOS. Time of discharge is difficult to 
determine in our EMR. As a result, we chose discontinuation of the vital signs order as a proxy for 
discharge time as it was a consistent event across admissions. Our average length of stay decreased from 
161.37 hours to 125.94 hours. In addition, the standard deviation narrowed from 141.59 hours to 82.34 
suggesting that implementation of a more standardized workflow decreased variation from one admission 
to another, which is an important component of a quality improvement initiative. One strength of this 
intervention was our inter-professional collaboration. We had champions at all touch points in the process 
making our PDSA cycles widely accepted.  
In conclusion, by implementing new admission workflows, optimizing our use of the EMR to 
communicate among providers, and improving pre-admission planning we were able to decrease time 
from admission to initiation of chemotherapy by 53.2%. Further interventions are needed in order to 
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